Inclusion Criteria:

• Patients entering the study will:

  • Be taking Avonex
  • Have normal laboratory blood tests and EKG
  • Be complaining of attention problems to treating neurologist

  • Be English-speaking males and females between the ages of 25 and 60, inclusive [If patient is female, she must

    • Be surgically sterile; or
    • Be 2 years postmenopausal; or
    • If of child-bearing potential, must be using a medically accepted method of birth control and agree to continue to use this method for the duration of the study (i.e., barrier method with spermicide, steroidal contraceptive [oral, implanted, and Depo-Provera contraceptives must be used in conjunction with a barrier method], IUD, or abstinence)]
  • Have clinically definite RR MS with disease duration of less than 10 years
  • Have an EDSS score between 0 and 5.5
  • Have corrected vision of no worse than 20/50
  • Have between 10 and 20 years of education
  • Be cerebral-stimulant free for at least one week prior to Attention Screening
  • Be able to complete self-rating scales and cognitive assessment tools
  • Have provided written informed consent
  • To have performed at least one standard deviation below normative expectation on at least two of four measures in the attention screening evaluation

Exclusion Criteria:

• Patients entering the study will NOT:

  • A history of heart disease or liver dysfunction
  • Have abnormal EKG or laboratory blood work,
  • Have a history of psychosis
  • Be a significant risk of suicide
  • Be abusing alcohol (current and within last 2 years)
  • Be abusing controlled substances (current and within last 2 years)
  • Have any medical ailment which can produce fatigue, such as lupus, anemia or thyroid disease
  • Have any history of clinical deviation from normal ranges in the physical examination
  • Have an unstable medical disorder, or medical contraindication to the use of Provigil
  • Have any history of head injury, seizures, or neurological conditions involving the central nervous system other than RR MS
  • Have any disorder that may interfere with drug absorption, distribution, metabolism, or excretion, including gastrointestinal surgery
  • Be a pregnant or lactating female (any patient becoming pregnant during the study will be discontinued)
  • Have received any investigational product within 30 days of Cognitive Screening
  • Have upper extremity dysfunction that prohibits them from using a computer mouse writing with a pencil
  • Be colorblind